Suppr超能文献

肝再次移植生存模型的验证与完善

Validation and refinement of survival models for liver retransplantation.

作者信息

Rosen Hugo R, Prieto Martin, Casanovas-Taltavull Teresa, Cuervas-Mons Valentin, Guckelberger Olaf, Muiesan Paolo, Strong Russell W, Bechstein Wolf O, O'grady John, Zaman Atif, Chan Benjamin, Berenguer Joaquin, Williams Roger, Heaton Nigel, Neuhaus Peter

机构信息

Division of Gastroenterology/Hepatology, Portland VAMC and Oregon Health and Science University, Portland, OR 97207, USA.

出版信息

Hepatology. 2003 Aug;38(2):460-9. doi: 10.1053/jhep.2003.50328.

Abstract

Orthotopic liver retransplantation (re-OLT) is highly controversial. The objectives of this study were to determine the validity of a recently developed United Network for Organ Sharing (UNOS) multivariate model using an independent cohort of patients undergoing re-OLT outside the United States, to determine whether incorporation of other variables that were incomplete in the UNOS registry would provide additional prognostic information, to develop new models combining data sets from both cohorts, and to evaluate the validity of the model for end-stage liver disease (MELD) in patients undergoing re-OLT. Two hundred eighty-one adult patients undergoing re-OLT (between 1986 and 1999) at 6 foreign transplant centers comprised the validation cohort. We found good agreement between actual survival and predicted survival in the validation cohort; 1-year patient survival rates in the low-, intermediate-, and high-risk groups (as assigned by the original UNOS model) were 72%, 68%, and 36%, respectively (P <.0001). In the patients for whom the international normalized ratio (INR) of prothrombin time was available, MELD correlated with outcome following re-OLT; the median MELD scores for patients surviving at least 90 days compared with those dying within 90 days were 20.75 versus 25.9, respectively (P =.004). Utilizing both patient cohorts (n = 979), a new model, based on recipient age, total serum bilirubin, creatinine, and interval to re-OLT, was constructed (whole model chi(2) = 105, P <.0001). Using the c-statistic with 30-day, 90-day, 1-year, and 3-year mortality as the end points, the area under the receiver operating characteristic (ROC) curves for 4 different models were compared. In conclusion, prospective validation and use of these models as adjuncts to clinical decision making in the management of patients being considered for re-OLT are warranted.

摘要

原位肝再次移植(re-OLT)极具争议性。本研究的目的是使用在美国境外接受再次移植的独立患者队列来确定最近开发的器官共享联合网络(UNOS)多变量模型的有效性,确定纳入UNOS登记中不完整的其他变量是否会提供额外的预后信息,开发结合两个队列数据集的新模型,并评估再次移植患者的终末期肝病模型(MELD)的有效性。6个国外移植中心的281例接受再次移植的成年患者(1986年至1999年之间)组成了验证队列。我们发现验证队列中的实际生存率与预测生存率之间具有良好的一致性;低、中、高风险组(根据原始UNOS模型分配)的1年患者生存率分别为72%、68%和36%(P<.0001)。在可获得凝血酶原时间国际标准化比值(INR)的患者中,MELD与再次移植后的结局相关;存活至少90天的患者与90天内死亡的患者相比,MELD中位数分别为20.75和25.9(P =.004)。利用两个患者队列(n = 979),构建了一个基于受者年龄、总血清胆红素、肌酐和再次移植间隔时间的新模型(整体模型卡方值= 105,P<.0001)。以30天、90天、1年和3年死亡率作为终点,使用c统计量比较了4种不同模型的受试者工作特征(ROC)曲线下面积。总之,有必要对这些模型进行前瞻性验证并将其用作考虑再次移植患者管理中临床决策的辅助工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验